CITY OF INDUSTRY, Calif., Jan. 6, 2026 /PRNewswire/ — AIC today announced the expansion of its NVIDIA BlueField accelerated storage portfolio with the introductionCITY OF INDUSTRY, Calif., Jan. 6, 2026 /PRNewswire/ — AIC today announced the expansion of its NVIDIA BlueField accelerated storage portfolio with the introduction

AIC Expands NVIDIA BlueField-Accelerated Storage Portfolio With New F2032-G6 JBOF Storage System to Accelerate AI Inference

2026/01/06 14:30
Okuma süresi: 3 dk

CITY OF INDUSTRY, Calif., Jan. 6, 2026 /PRNewswire/ — AIC today announced the expansion of its NVIDIA BlueField accelerated storage portfolio with the introduction of the F2032-G6 2U JBOF storage system, optimized for accelerating AI inference by storing KV cache context. Featuring a High Availability, dual-active node architecture that provides full resiliency for mission-critical workloads, the platforms deliver next-generation performance, capacity, and availability for flash-based storage deployments.

The F2032-G6 JBOF integrates two or four NVIDIA BlueField-4 DPUs, each with 800Gb/s throughput, and can also support NVIDIA ConnectX-9 SuperNICs. It supports NVIDIA DOCA microservices to deliver breakthrough acceleration for the NVIDIA Inference Context Memory Storage Platform. A dual-port design enables link redundancy and continuous operation for high-throughput storage services in scalable, distributed environments.

Designed for extremely efficient flash configurations, the platform supports up to 32 E3.S/L NVMe drives, enabling up to 8 PB of storage in a single 2U chassis using 15, 30, 60, 122 or 256 TB SSDs. This compact system architecture provides enterprises and cloud operators a scalable building block for high-performance, power-efficient flash tiers.

“As data demands continue to grow at unprecedented rates, AIC is fully committed to BlueField-4 the NVIDIA BlueField platform as a storage controller,” said Michael Liang, President and CEO of AIC. “The F2032-G6 delivers resilient, high-performance, and scalable flash storage that empowers critical workloads with unmatched speed, reliability, and efficiency.”

“The increasing complexity of AI inference and reasoning workloads requires a fundamental architectural shift to unify compute, network, and storage for unprecedented efficiency and scale,” said Yael Shenhav, VP Networking, NVIDIA. “NVIDIA is collaborating with AIC to bring accelerated, AI-native data storage platforms, powered by the BlueField-4 DPU, to scaleAI inference in the agentic era.”

These new systems are ideal for modern workloads, including:

  • KV cache context storage for AI inference
  • Parallel and scale-out file systems
  • Large-scale object storage
  • Mission-critical enterprise flash tiers

AIC continues to strengthen its collaboration and product alignment with NVIDIA and remains committed to full support of the BlueField-4 ecosystem across future platforms.

About AIC Inc.
AIC Inc. is a global leader in server and storage solutions. With nearly 30 years of expertise in high-density storage servers, storage server barebones, and high-performance computers, AIC has expanded into AI storage and AI edge appliances, achieving significant market recognition for its branded products. The company’s in-house design, manufacturing, and validation capabilities ensure products are highly flexible and configurable to meet diverse form factor requirements. Headquartered in Taiwan, AIC operates offices and facilities across the United States, Asia, and Europe. For more information, please visit www.aicipc.com or contact us at sales@aicipc.com.

Cision View original content:https://www.prnewswire.com/news-releases/aic-expands-nvidia-bluefield-accelerated-storage-portfolio-with-new-f2032-g6-jbof-storage-system-to-accelerate-ai-inference-302653446.html

SOURCE AIC Inc.

Piyasa Fırsatı
AI COMPANIONS Logosu
AI COMPANIONS Fiyatı(AIC)
$0.074366
$0.074366$0.074366
-3.03%
USD
AI COMPANIONS (AIC) Canlı Fiyat Grafiği
Sorumluluk Reddi: Bu sitede yeniden yayınlanan makaleler, halka açık platformlardan alınmıştır ve yalnızca bilgilendirme amaçlıdır. MEXC'nin görüşlerini yansıtmayabilir. Tüm hakları telif sahiplerine aittir. Herhangi bir içeriğin üçüncü taraf haklarını ihlal ettiğini düşünüyorsanız, kaldırılması için lütfen service@support.mexc.com ile iletişime geçin. MEXC, içeriğin doğruluğu, eksiksizliği veya güncelliği konusunda hiçbir garanti vermez ve sağlanan bilgilere dayalı olarak alınan herhangi bir eylemden sorumlu değildir. İçerik, finansal, yasal veya diğer profesyonel tavsiye niteliğinde değildir ve MEXC tarafından bir tavsiye veya onay olarak değerlendirilmemelidir.

Ayrıca Şunları da Beğenebilirsiniz

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Paylaş
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Paylaş
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Paylaş
BitcoinEthereumNews2025/09/18 05:26